Abstracts tagged "Lupus nephritis"

Abstract Number: LB04 • ACR Convergence 2025
Anti-CD20/BCMA Bispecific CAR-T Cell Therapy Promotes Immune Reset and Sustained Drug Free Remission in Refractory Autoimmune Diseases
Huihua Ding¹, Wensi Li², Yiwen Shen³, Chunyan Zhang⁴, Yan Ye³, Ran Wang³, Shaoying Yang³, Chunmei Wu³, Dai Dai³, Chengxiao Zheng², Yuan Qian², Xiaobing Luo⁵, Thule Trinh⁵, Judy Zhu², Jiaqi Huang⁵, Yong Hao³, Xiaoying Yao³, Zhenfen Ling⁶, Yihong Yao⁵ and Nan Shen¹, ¹Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ²Shanghai AbelZeta Ltd., Shanghai, China (People's Republic), ³Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China, ⁵AbelZeta Inc., Rockville, ⁶Shanghai General Hospital, Shanghai, China (People's Republic)
Background/Purpose: Refractory autoimmune diseases with progressive organ damage remain a major unmet medical need. C-CAR168 is an autologous anti-CD20/BCMA bispecific CAR-T therapy designed to simultaneously…
Abstract Number: LB13 • ACR Convergence 2025
Obinutuzumab Leads to Deep B-Cell Depletion in the Kidney Parenchyma of Patients With Lupus Nephritis: An Exploratory Analysis of the REGENCY Trial
Brad Rovin¹, Elsa Martins², Cary Austin³, Harini Raghu³, Caleb Chan³, Patrick Chang³, Jay Garg³, Valeria Alberton⁴, Mittermayer Santiago⁵, Gustavo Aroca-Martínez⁶, Fedra Palazuelos⁷, Teresa Baczkowska⁸, José Alfaro⁹, Jorge Ravelo-Hernández¹⁰, Richard Furie¹¹, Luís Pinto¹², Eduardo Albiero¹³, Christopher Larsen¹⁴, Bongin Yoo³, Jennifer Pulley¹⁵, Andrew Thorley³, Thomas Schindler², Theodore Omachi³, William Pendergraft III³ and Ana Malvar¹⁶, ¹Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, Ohio, ²F. Hoffmann-La Roche Ltd, Basel, Switzerland, ³Genentech, Inc., South San Francisco, California, ⁴Pathology Unit, Fernández Hospital, Buenos Aires, Argentina, ⁵Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Brazil, ⁶Universidad Simón Bolívar y Clínica de la Costa, Barranquilla, Colombia, ⁷Centro de Investigación y Tratamiento Reumatológico S.C., Mexico City, Mexico, ⁸Department of Transplantation Medicine, Nephrology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland, ⁹Instituto Peruano del Hueso y la Articulación, Lima, Peru, ¹⁰Clinica San Juan Bautista, Unidad de Investigacion en Reumatologia e Inmunologia, Lima, Peru, ¹¹Division of Rheumatology, Northwell Health, Great Neck, New York, ¹²Internal Medicine and Rheumatology, Hospital Pablo Tobón Uribe, Medellín, Colombia, ¹³Sanatorio Allende, Córdoba, Argentina, ¹⁴Arkana Laboratories, Little Rock, Arkansas, ¹⁵Roche Products Ltd, Welwyn Garden City, United Kingdom, ¹⁶Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: B cells infiltrate the kidneys in lupus nephritis (LN) and likely contribute to the pathogenesis of kidney injury. The REGENCY trial (NCT04221477) showed that…
Abstract Number: 0839 • ACR Convergence 2025
Precision Liquid Biopsy for Lupus Nephritis: cfDNA Methylation and Fragmentomic Signatures Enable Non-Invasive Diagnosis and Dynamic Disease Tracking
Qiuyu Jing¹, Qiang Li², Chiu Wai Shirley Chan³, Weixin Chen⁴, Fung Yu Nick choi⁴, Iris Tang⁵, Chak Sing Lau⁶, Heidi Ling⁶, Jason Wong⁷ and Philip Li², ¹Center for Oncology & Immunology, Hong Kong, Hong Kong, ²Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ³Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, ⁴School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, ⁵Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong, ⁶The University of Hong Kong, Hong Kong, Hong Kong, ⁷School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hing Kong, Hong Kong
Background/Purpose: Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), lacks reliable non-invasive biomarkers for early detection and monitoring. This study investigates plasma…
Abstract Number: 0642 • ACR Convergence 2025
Belimumab-Based Triple Therapy in Proliferative Lupus Nephritis: Renal Outcomes and Glucocorticoid Tapering in a Real-World Multicenter Cohort
Paola Vidal Montal¹, Javier Narváez², Aina Fabregat³, Iñigo Rúa-Figueroa⁴, José María Pego-Reigosa⁵, Andrea Hernández-martín⁶, Clara Moriano⁷, Maria Garcia-Villanueva⁸, Sandra Garrote Corral⁹, Sergi Heredia¹⁰, Julia Martínez Barrio¹¹, Júlia Bernardez Moreno¹², Paloma Vela Casasempere¹³, Beatriz Tejera Segura¹⁴, Leyre Riancho¹⁵, Francisco Javier Novoa¹⁶, Vicenç Torrente-Segarra¹⁷, Maria Piqueras García¹⁸, Beatriz Frade Sosa¹⁹, José Gomez-Puerta²⁰, Consuelo Ramos Giraldez²¹, Tarek Salman Montes²², María Galindo-Izquierdo²³, EVA GLORIA TOMERO MURIEL²⁴, Jaime calvo²⁵, Jorge Juan Fragío Gil²⁶, Marta De la Rubia Navarro²⁷, Berta Magallares²⁸ and Irene Altabás-González²⁹, ¹Bellvitge University Hospital, Barcelona, Spain, ²Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Rheumatology. Hospital Universitario de Bellvitge., Barcelona, Spain, ⁴Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ⁵Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ⁶Hospital Universitario de Gran Canaria Dr Negrín, Las palmas, Spain, ⁷Hospital León, LEON, Castilla y Leon, Spain, ⁸Hospital Ramón y Cajal, Madrid, Spain, ⁹Hospital Ramón y Cajal, Madrid, ¹⁰Hospital Moisès Broggi, Barcelona, Spain, ¹¹Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ¹²Hospital de Sant Pau, Barcelona, Spain, ¹³Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁴Hospital Insular de Gran Canaria, Las palmas, Spain, ¹⁵Hospital de Sierrallana, Torrelavega, ¹⁶Hospital Insular de Gran Canaria, Las palmas, ¹⁷Hospital Comarcal Alt Penedés Garraf, Vilafranca del Penedès, Spain, ¹⁸Servicio Murciano de Salud, Murcia, Spain, ¹⁹Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ²⁰Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain, ²¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ²²Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²³Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Madrid, Spain, ²⁴Hospital Universitario de la Princesa, Madrid, Spain, ²⁵Hospital de Araba, Vitoria, Spain, ²⁶Hospital General Universitario, Valencia, Spain, ²⁷Hospital de La Fe, Valencia, ²⁸Hospital de Sant Pau, Bareclona, ²⁹Complejo Hospitalario de Vigo, Vigo, Spain
Background/Purpose: The newly published ACR guidelines recommend initiating triple therapy for all patients with proliferative lupus nephritis (LN). While belimumab (BEL) has demonstrated efficacy in…
Abstract Number: 0981 • ACR Convergence 2025
GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases
Christopher Moore¹, Travis Drow², Peter Cook², Annaiz Grimm², Victoria DeVault-Nelson¹, Jennifer Mellen¹, Payam Zarin¹, Alaina Burgess¹, Maegan Hoover¹, Tingxi Guo¹, Brock McKinney², Noelle Dahl², Aesha Vakil², Brian Christin³, Gene Uenishi¹, Tiffany Chen¹, Alberto Del Rio-Espinola⁴, David Rawlings² and Tom Wickham¹, ¹GentiBio, Cambridge, ²SCRI, Seattle, ³GentiBio, Seattle, ⁴GentiBio, Basel, Switzerland
Background/Purpose: CD19 CAR T therapies have demonstrated promise in systemic lupus erythematosus (SLE) by transiently depleting B cells and resetting the immune system. However, long-term…
Abstract Number: 1520 • ACR Convergence 2025
Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Bahtiyar Toz¹, Himanshu Vashistha² and Richard Furie³, ¹Zucker School of Medicine at Hofstra/ Northwell, Queens, NY, ²Northwell Health, Great Neck, NY, ³Division of Rheumatology, Northwell Health, Great Neck, NY
Background/Purpose: Biologic treatments for lupus nephritis (LN) have improved short-term outcomes. Obinutuzumab (OBI), an anti-CD20 monoclonal antibody, demonstrated efficacy in the NOBILITY and REGENCY trials;…
Abstract Number: 1841 • ACR Convergence 2025
Differential metabolomic signatures along lupus nephritis spectrum
Mariana Jiménez Tirado¹, karina santana², Jiram Torres Ruiz³, Jennifer Tiaré Balderas Miranda⁴, Diana Gómez-Martín⁵, José Carlos Páez Franco⁶, Nancy R Mejía Domínguez⁷, Hilda Sánchez Vidal⁶ and Imelda Cecilia Zarzoza Mendoza⁸, ¹Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ²INCMNSZ, Ciudad de México, Federal District, Mexico, ³INCMNSZ, Mexico, Federal District, Mexico, ⁴Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, ⁵INCMNSZ, Mexico city, Federal District, Mexico, ⁶Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Distrito Federal, Mexico, ⁷Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁸Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico
Background/Purpose: Lupus nephritis (LN) is a common feature in systemic lupus erythematosus (SLE) affecting up to 50% of the individuals with this disease. The gold…
Abstract Number: 2438 • ACR Convergence 2025
SGLT2 Inhibitors in SLE: Impact on Pulmonary Hypertension, Mortality, and Renal Outcomes
Ahmad Alomari¹, Asim Khanfar², Miguel Rodriguez³ and Diala Alawneh⁴, ¹UCF- North Florida hospital, Gainesville, FL, ²Rochester General Hospital, Rochester, NY, ³SIMED Rheumatology, Gainesville, FL, ⁴University of Florida, Gainesville, FL
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease linked to significant morbidity, including pulmonary hypertension (PH). While SGLT2 inhibitors are known for cardiovascular…
Abstract Number: 0840 • ACR Convergence 2025
Shared and Distinct Urinary Proteomic Signatures of Lupus Nephritis and Other Glomerular Diseases
Alessandra Ida Celia¹, Daksh Saksena², CHEN-YU LEE³, Carla Guthridge⁴, Wade DeJager⁵, Rufei Lu⁴, Judith James⁴, Jill Buyon⁶, Michelle Petri⁷, Joel Guthridge⁴, Brad Rovin⁸ and Andrea Fava³, ¹Sapienza University of Rome, Rome, Italy, ²Johns Hopkins University, Baltimore, ³Johns Hopkins University, Baltimore, MD, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Johns Hopkins University School of Medicine, Timonium, MD, ⁸The Ohio State University, Columbus, OH
Background/Purpose: Urine collects the byproducts of kidney biology and has emerged as a valuable, noninvasive source of molecular information that reflects intrarenal pathology. In lupus…
Abstract Number: 0650 • ACR Convergence 2025
Obinutuzumab Demonstrates Steroid-Sparing Effects and Consistent Benefit In Patients with Lupus Nephritis When Using Multiple Primary Endpoint Definitions: A Secondary Analysis of Phase III Trial Results
Brad Rovin¹, Jay Garg², Richard Furie³, Rachel Jones⁴, Amit Saxena⁵, Pasquale Esposito⁶, Elsa Martins⁷, Claire Petry⁷, Nicolas Frey⁷, Bongin Yoo², Imran Hassan⁸, Thomas Schindler⁷, Theodore Omachi⁹, William Pendergraft², Mittermayer Santiago¹⁰, Gustavo Aroca Martínez¹¹ and Ana Malvar¹², ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, ⁶Clinica Nefrologica, Dialisi, Trapianto, Department of Internal Medicine, University of Genoa and IRCCS Ospedale Policlinico San Martino, Genova, Italy, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁹Genentech, Inc., South San Francisco, ¹⁰Bahiana School of Medicine and Public Health and UFBA, Federal University of Bahia, and Clínica SER da Bahia, Salvador, Bahia, Brazil, ¹¹Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ¹²Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: The Phase III REGENCY study (NCT04221477) demonstrated superiority of obinutuzumab (OBI) over placebo (PBO) in achieving complete renal response (CRR) at Week 76 when…
Abstract Number: 1038 • ACR Convergence 2025
Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States
Anisha Patel¹, Alexandra Miller¹, Lisa Lindsay¹, Danny Sheinson¹, Zhiyu Xia¹, William Pendergraft¹ and Maria Dall'Era², ¹Genentech, Inc., South San Francisco, CA, ²Division of Rheumatology, University of California, San Francisco, CA
Background/Purpose: LN is a severe manifestation of SLE requiring intensive management. We aimed to characterize real-world treatment patterns in newly diagnosed patients with LN within…
Abstract Number: 1521 • ACR Convergence 2025
Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Brad Rovin¹, William Pendergraft², Liz Lightstone³, Eric Daugas⁴, Richard Furie⁵, Theodore Omachi², Imran Hassan⁶, Elsa Martins⁷, Thomas Schindler⁷, Jay Garg², Luis Quintana⁸, Piotr Leszczyński⁹ and Ana Malvar¹⁰, ¹The Ohio State University, Columbus, OH, ²Genentech, Inc., South San Francisco, CA, ³Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁴Department of Nephrology, Hospital Bichat - Claude-Bernard, Paris, France, ⁵Division of Rheumatology, Northwell Health, Great Neck, NY, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷F. Hoffmann-La Roche Ltd, Basel, Switzerland, ⁸Department of Nephrology, Hospital Clinic, Barcelona, Spain, ⁹Department of Internal Medicine and Metabolic Diseases, Poznan University of Medical Sciences, Poznan, Poland, ¹⁰Organización Médica de Investigación, Buenos Aires, Argentina
Background/Purpose: Lupus nephritis (LN) is the most common, severe, organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, double-blind, placebo-controlled, Phase III REGENCY trial (NCT04221477)…
Abstract Number: 1843 • ACR Convergence 2025
Tissue Neutrophils in The Pathogenesis of Lupus Nephritis
Norio Hanata¹, Carmelo Carmona-Rivera¹, Victoria Hoffman², Kan Jiang³, davide Randazzo⁴, Meryl Waldman⁵, Sarfaraz Hasni⁶ and Mariana Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ²Diagnostic and Research Services Branch, Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, Bethesda, ³Biodata Mining and Discovery Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁴Light Imaging Section, Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, ⁵Kidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, Bethesda, PA, ⁶National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease that frequently affects the kidneys, with lupus nephritis (LN) being a major contributor to morbidity…
Abstract Number: 2439 • ACR Convergence 2025
Belimumab Versus Mycophenolate Mofetil in Lupus Nephritis: A Real-World Comparative Analysis
Ahmad Alomari¹, Nikita Shah², Miguel Rodriguez³ and Diala Alawneh⁴, ¹UCF- North Florida hospital, Gainesville, FL, ²UCF/HCA Florida North Florida Hospital, Gainesville, FL, ³SIMED Rheumatology, Gainesville, FL, ⁴University of Florida, Gainesville, FL
Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), often leading to chronic kidney disease (CKD) and end-stage renal disease (ESRD).…
Abstract Number: 0841 • ACR Convergence 2025
Comparing the Impact of GLP-1 Agonists and SGLT-2 Inhibitors on Outcomes in Lupus Nephritis: A Retrospective Cohort Study
Kinga Grzybowski¹ and Irene Tan², ¹Jefferson Einstein Montgomery Hospital, Maspeth, NY, ²Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Lupus Nephritis (LN) is one of the most serious complications of SLE (Systemic Lupus Erythematosus) characterized by an attack of the kidneys by the…

1
2
3
…
44
Next Page »

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].